These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 10811462

  • 1. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
    Lin CP, Huang MJ, Chang IY, Lin WY.
    Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
    [Abstract] [Full Text] [Related]

  • 2. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK, Gillan E, Quinn JJ, Altman AJ.
    J Pediatr Hematol Oncol; 1998 Jun; 20(6):545-7. PubMed ID: 9856675
    [Abstract] [Full Text] [Related]

  • 3. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y, Komatsu H, Ishii K, Nakamura F, Hayashi T, Sawada H, Ono Y, Imanaka T.
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [Abstract] [Full Text] [Related]

  • 4. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY, Yang CH, Chen YC.
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [Abstract] [Full Text] [Related]

  • 5. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin, Huang MJ, Chang IY, Lin WY, Sheu YT.
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [Abstract] [Full Text] [Related]

  • 6. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y.
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [Abstract] [Full Text] [Related]

  • 7. Long-term survey of outcome in acute promyelocytic leukemia.
    Hu J, Shen Z, Sun H, Wu W, Li X, Sun G, Wang Z.
    Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
    [Abstract] [Full Text] [Related]

  • 8. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T, Westervelt P, Hess JL.
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [Abstract] [Full Text] [Related]

  • 9. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH.
    J Natl Cancer Inst; 1998 Jan 21; 90(2):124-33. PubMed ID: 9450572
    [Abstract] [Full Text] [Related]

  • 10. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
    Shinjo K, Takeshita A, Sahara N, Kobayashi M, Nakamura S, Shigeno K, Naito K, Maekawa M, Ohnishi K, Ohno R.
    Intern Med; 2005 Aug 21; 44(8):818-24. PubMed ID: 16157979
    [Abstract] [Full Text] [Related]

  • 11. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K, Kiyoi H, Yoshida H, Tobita T, Takeshita A, Ohno R, Naoe T.
    Cancer Chemother Pharmacol; 1997 Aug 21; 40 Suppl():S36-41. PubMed ID: 9272132
    [Abstract] [Full Text] [Related]

  • 12. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A, Kizaki M, Kawamura C, Matsushita H, Fukuchi Y, Umezawa A, Yamada T, Hata J, Hozumi N, Yamato K, Ito M, Ueyama Y, Ikeda Y.
    Leukemia; 2001 Aug 21; 15(8):1176-84. PubMed ID: 11480559
    [Abstract] [Full Text] [Related]

  • 13. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y, Zhang L, Wu J, Lu A, Wang B, Liu G.
    Eur J Haematol; 2013 Dec 21; 91(6):483-9. PubMed ID: 24033687
    [Abstract] [Full Text] [Related]

  • 14. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L, Mohassel L.
    Am J Health Syst Pharm; 2009 Nov 01; 66(21):1913-8. PubMed ID: 19850784
    [Abstract] [Full Text] [Related]

  • 15. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N.
    Ann Oncol; 2006 Jan 01; 17(1):131-4. PubMed ID: 16227315
    [Abstract] [Full Text] [Related]

  • 16. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
    Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY.
    Blood; 1997 May 01; 89(9):3354-60. PubMed ID: 9129042
    [Abstract] [Full Text] [Related]

  • 17. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY.
    Semin Hematol; 2001 Jan 01; 38(1):26-36. PubMed ID: 11172537
    [Abstract] [Full Text] [Related]

  • 18. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
    Zhang X, Zhou H, Song S, Qiao Z, Yang L, Hu Y.
    Zhonghua Nei Ke Za Zhi; 2001 Dec 01; 40(12):829-33. PubMed ID: 16206674
    [Abstract] [Full Text] [Related]

  • 19. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE.
    Br J Haematol; 2015 Nov 01; 171(4):471-7. PubMed ID: 26205361
    [Abstract] [Full Text] [Related]

  • 20. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ.
    Blood; 1999 Nov 15; 94(10):3315-24. PubMed ID: 10552940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.